Latham & Watkins Advises Chugai Pharmaceutical in US$1.085 Billion License Agreement With Rani Therapeutics

Chugai Pharmaceutical Co., Ltd. (TOKYO: 4519, Chugai) and Rani Therapeutics, LLC, a subsidiary of Rani Therapeutics Holdings, Inc. (Nasdaq: RANI, Rani), a biotherapeutics company focused on the oral delivery of biologics and drugs, announced that they have entered into a Collaboration and License Agreement for the development and commercialization of an oral product consisting of Rani’s oral delivery technology, the RaniPill®, and Chugai’s rare disease antibody in development.

Latham & Watkins, LLP is advising Chugai in the transaction with a corporate deal team led by San Diego/Bay Area partner Chris Hazuka and San Diego counsel Darryl Steensma, with associates Mizuna Sekine and Patrick Chew. Advice was also provided on finance matters by Los Angeles partner Ted Dillman; on securities matters by Bay Area partner Kathleen Wells; and on tax matters by Bay Area partner Kirt Switzer, with associate Derek Gumm.